A polypill is the solution to the pharmacological management of cardiovascular risk: yes.
Elley
C Raina
CR
Department of General Practice and Primary Health Care, Faculty of Medical and Health Sciences, The University of Auckland, PB 92019 Auckland, New Zealand. c.elley@auckland.ac.nz
D000924:Anticholesteremic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000959:Antihypertensive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000208:ethnology / Q000517:prevention & control*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008017:Life Expectancy; D008297:Male; D055118:Medication Adherence; D009520:New Zealand / Q000453:epidemiology; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D010818:Practice Patterns, Physicians'
D000924:Anticholesteremic Agents; D000959:Antihypertensive Agents; D004338:Drug Combinations; D010975:Platelet Aggregation Inhibitors